| Name | Title | Contact Details |
|---|
Sports Performance International is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rheonix, Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. As scientific knowledge evolves, so does the need for new diagnostic technology to simplify processes and enhance innovation. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy to use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in-between.
Syntimmune approaches areas of high unmet medical need in a unique way. Instead of searching for novel, unproven disease biology, Syntimmune focuses on areas of science that are well understood and extensively researched. We seek new treatments that build on these areas of scientific consensus and broad applicability. In the case of our lead drug candidate, SYNT001, both the cellular pathway and the specific molecular target have been studied extensively for more than 25 years, spearheaded by the groundbreaking research of the scientific team behind Syntimmune. Building on proven areas of science enables Syntimmune to advance its drug candidates swiftly and predictably. The result is a significantly derisked approach to new drug development. More importantly, we believe our approach speeds approval of medicines for patients in areas where existing treatments involve inconvenience, dangerous side effects, or poor efficacy. In an industry that often places a premium on novelty, Syntimmune understands that creating real value comes from helping patients who are suffering with diseases for which current treatments are inadequate or nonexistent.
DMC is leading the low cost sustainable transformation of multiple product markets.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.